HCM (HUTCHMED Ltd) Net earnings per share (EPS TTM)

Public company logo of HUTCHMED (China) Limited (HCM)

HUTCHMED (China) Limited combines robust drug distribution in the PRC with the development of cutting-edge precision oncology therapies and targeted inhibitors. The TTM net income per share distribution reflects revenue dynamics, where 0.10 captures the current state of the parameter. Despite sales growth, the high cost of R&D projects is temporarily hindering the company's transition to stable operating profitability.

HCM HUTCHMED (China) Limited Net earnings per one share for the last twelve months (07/04/2022 - 11/16/2026)

Analytical breakdowns and data insights for company HUTCHMED Ltd (HCM)

- current quotes and average value forecast:
Comprehensive company analysis:HUTCHMED Corp - HCM
Mass-produced product of Hutchison MediPharma

EPS TTM measures the final profit per ordinary share over a trailing twelve-month period, allowing for an assessment of real capital efficiency without the impact of quarterly fluctuations. By analyzing the annual EPS TTM snapshot, an investor can see how the diversification of HUTCHMED (HCM) production chains across the US and Asia protects margins from regulatory risks, confirming the long-term financial stability of the biotech holding.

Main competitors

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Nuvation Bio Inc|Day One (DAWN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months MNPR|INBX (inhibrx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months i-mabbiopharma.com (IMAB)|Earnings per share for the last twelve months Fennec (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months